INDV · Indivior Pharmaceuticals, Inc.

$39.01 +0.79 (+2.07%) At close · Aug 14

Market Cap

$4.60B

118.01M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joe Ciaffoni	Chief Executive Officer	$680,114	—	$15,319,404	—	$2,100,000	$401,696	$18,501,214
Pat Barry Chief	Commercial Officer	$408,333	$300,000	$3,247,375	—	$840,000	$110,036	$4,905,744
Christian Heidbreder	—	$652,628	—	$2,689,676	—	$783,154	$57,090	$4,182,548
Richard Simkin	—	$325,008	—	$2,968,661	—	$448,778	$274,869	$4,017,316
Ryan Preblick	Chief Financial Officer	$558,820	—	$2,303,067	—	$670,584	$59,922	$3,592,393
Jeff Burris	—	$569,001	—	$2,337,861	—	$569,000	$45,353	$3,521,215
Mark Crossley	—	$902,261	—	$162,518	—	$2,054,522	$66,290	$3,185,591

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Former Chief	Executive Officer	$871,750	—	$2,650,843	—	$268,063	$62,862	$3,853,518
Chief Scientific	Officer	$630,558	—	$1,663,461	—	$155,117	$57,861	$2,506,997
Ryan Preblick	Chief Financial Officer	$539,922	—	$1,554,627	—	$132,821	$54,194	$2,281,564
Chief Legal	Officer	$500,861	—	$1,321,313	—	$102,677	$44,925	$1,969,776

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Former Chief	Executive Officer	$834,210	—	$2,435,038	—	$1,063,618	$58,375	$4,391,241
Chief Scientific	Officer	$603,405	—	$1,556,976	—	$615,473	$76,274	$2,852,128
Ryan Preblick	Chief Financial Officer	$516,672	—	$1,432,717	—	$395,254	$52,489	$2,397,132
Chief Legal	Officer	$474,750	—	$1,225,004	—	$403,538	$98,798	$2,202,090

Executive changes

Person	Role	Change	Effective	Filed
Christian Heidbreder	Chief Scientific Officer	Terminated	2026-12-31	2026-05-15
Stuart A. (Tony) Kingsley	non-executive director	Appointed	2025-07-01	2025-06-24
Mark Crossley	director	Resigned	2025-05-08	2025-05-08
Mark Crossley	CEO	Resigned	2025-05-08	2025-05-08
Joe Ciaffoni	CEO	Appointed	2025-05-08	2025-05-08
Robert Schriesheim	Director	Resigned	2025-03-02	2025-03-04

Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 317 filings 316 filers Visit website Investor relations